A nomogram incorporating Ki67 to predict survival of acral melanoma

Acral melanoma (AM), arising on the non-hair-bearing skin of the palms, soles or subungual regions, is a rare melanoma type in Western populations (Markovic et al. 2007). However, it is the most common subtype in Asian, African and Hispanic populations, constituting up to 40–75% of color populations (Chen et al. 2020; Desai et al. 2017). Compared with cutaneous melanoma from other sites, AM is associated with worse prognosis and poorer survival because of delayed diagnosis (Carrera and Puig-Butille 2018; Desai et al. 2017; Teramoto et al. 2018). Genomically, AM shows lower mutational burdens, different oncogenic drivers and a higher number of structural chromosomal changes (Chen et al. 2020; Shi et al. 2022). While immunotherapies and target therapies have significantly improved the survival of patients with cutaneous melanoma, these therapies are less effective or are ineffective for most patients with AM. Many risk factors, including age, Breslow thickness, ulceration status, stage, primary site, distant metastasis and lactate dehydrogenase (LDH) level have been shown to be correlated with prognosis in AM patients (Teramoto et al. 2018; Wang et al. 2021; Wei et al. 2020; Wei et al. 2022a,b). However, these results are controversial for some variables. An analysis of 853 AM patients in China depicted the prognostic value of Breslow thickness in AM, but no association was found between tumor thickness and survival in patients with Breslow thickness > 2 mm (Wei et al. 2022a). Interestingly, ulceration was found to have varying impact on prognosis across Breslow thickness. For patients with Breslow thickness ≤ 1 mm, ulceration was significantly associated with prognosis, while for patients with Breslow thickness > 1 mm, no correlation was found (Wei et al. 2022b). Wei et al. discovered that sole melanoma had worse survival compared with other subtypes (Wei et al. 2020), but subungual melanoma was considered to have worse survival than palm or sole melanoma in a previous study in Japan (Nakamura et al. 2020). The American Joint Committee on Cancer (AJCC) staging system for tumor-node-metastasis (TNM) remains the primary tool for prognostic prediction, but it has limitations because patients at the same stage can have vastly different survival outcomes (Gershenwald et al. 2017). Therefore, it is crucial to identify additional prognostic predictors and construct new predictive models for AM.

The Ki67 protein is an indicator of proliferative activity expressed in all phases of the cell cycle except G0. It has been extensively evaluated in various malignant tumor types, especially in breast cancer. Many studies have demonstrated that high Ki67 expression (with a cut-off value of 30% for the percentage of Ki67-expressing cells) is associated with poor prognosis and can predict anti-tumor therapy efficacy in breast cancer (Kurebayashi et al. 2014; Shao et al. 2021; Zhu et al. 2020). In melanoma, Ki67 expression has been proposed as a biomarker of metastasis and predictor of prognosis (Gimotty et al. 2005; Ladstein et al. 2010). However, the results of studies have not been consistent. As for AM, Wang et al. summarized and analyzed the characteristics and prognostic factors of 211 AM patients in China, and the results showed that Ki67 index in a continuous format was independently associated with prognosis (Wang et al. 2021). However, to the best of our knowledge, there are no additional studies confirming the predictive value of Ki67 in AM and no prognostic models have been previously established based on Ki67 expression for AM. Hence, this study aimed to summarize the clinicopathological and survival features across different Ki67 levels in AM patients and generate a predictive model to predict the survival of patients with AM.

AM, the most common melanoma subtype in Asia and Africa, is characterized by poor survival due to its more advanced stage at diagnosis as well as negative prognostic and genetic features (Carrera and Puig-Butille 2018; Lv et al. 2016). A series of publications have reported various prognostic markers for melanoma survival, but the results are controversial among those studies. The proliferation marker Ki67 has been discovered to be linked to survival of many malignancies, including melanoma. However, the prognostic status of Ki67 for patients with AM is less known. In this regard, we analyzed in this study the relationship between Ki67 and the clinicopathological and survival profiles of patients with AM and developed a nomogram prediction model to predict MSS of patients with AM at 1, 3, 5, and 8 years. To the best of our knowledge, this study has used the largest sample size to elucidate the relationship between Ki67 and AM and is the first study to build a model incorporating Ki67 for predicting survival of AM in a Chinese population.

Ki67 as a biomarker reflecting cell proliferation rate has been explored in predicting chemotherapy response and prognosis in various tumors. A series of studies have demonstrated that high Ki67 expression is correlated with poor prognosis in prostate, lung, serous ovarian, clear-cell renal cell and pancreatic cancers (Adams et al. 2009; Gayed et al. 2014; Genç et al. 2018; Lei et al. 2013; Pascale et al. 2016,). In particular, Ki67 expression has been used as an index to classify patients with breast cancer into different risk categories and to guide adjuvant or neoadjuvant therapy (Aleskandarany et al. 2011; Chen et al. 2018; Petrelli et al. 2015). Additionally, a series of studies found a correlation between Ki67 and patients with melanoma. Ki67 is known to be increased in melanoma and not in nevi, which could help pathologists to distinguish melanoma from nevus in challenging cases (Nielsen et al. 2012; Torres-Cabala et al. 2020). In cutaneous melanoma, overexpression of Ki67 was demonstrated to correlate with tumor grade, metastasis, melanoma-specific mortality, disease-free survival and overall survival (Gimotty et al. 2005; Nielsen et al. 2013; Väisänen et al. 2011). In mucosal melanoma, a few studies have indicated that Ki67 is a predictive indicator for both survival and adjuvant chemotherapy (Ben-Izhak et al. 2002; Kim et al. 2008; Tang et al. 2022). However, scanty information about the relationship between Ki67 and AM is available. There has only been one retrospective study depicting the prognostic value of Ki67 in AM patients. From analysis of a single-center series of 211 AM patients, Wang et al. found that the Ki67 index in a continuous format was independently associated with survival (Wang et al. 2021). In the present study, we enrolled 314 AM patients and summarized their clinicopathologic characteristics. The results suggested that Ki67 index in a continuous format correlated with MSS, which is consistent with the findings of Wang et al. In addition, we divided patients into two groups based on a cut-off Ki67 value of 30% and observed significantly favorable MSS for patients with Ki67 < 30% compared to patients with Ki67 ≥ 30%. In multivariate analysis, high Ki67 expression was an independent indicator of poor MSS in AM patients, which provided evidence that Ki67 expression could be used as a stratification factor to predict survival in AM patients in the future. In breast cancer, patients with high Ki67 expression (> 30%) had worse disease-free survival and overall survival after adjuvant tamoxifen therapy (Elzawahry et al. 2013), while they could benefit from chemotherapy (Criscitiello et al. 2014). Interestingly, Tang et al. discovered that for patients with Ki67 ≥ 30%, relapse-free survival was longer with temozolomide-based adjuvant chemotherapy compared to high-dose interferon-α2b adjuvant therapy (Tang et al. 2022). Whether Ki67 can play a similar role in AM warrants further investigation.

Among 314 AM patients, 49.4% of patients showed Ki67 ≥ 30% at diagnosis in our study. With respect to Breslow thickness, the percentage of patients with thickness > 4 mm was higher in patients with high Ki67 expression than in the low Ki67 group, and this was comparable to another study in which tumors with high Ki67 expression (> 10%) were thicker than those with low Ki67 expression (Väisänen et al. 2011). With regard to ulceration, tumors with low Ki67 were less likely to appear with ulceration. Furthermore, patients in the Ki67-high group tended to present at a later stage, with more lymph node metastases and distant metastasis. Ki67 expression was significantly lower in patients with nonmetastatic disease (stage I/II) than in those with metastatic disease (stage III/IV), but there was no difference between either stage I vs. II or stage III vs. IV. Other characteristics such as age, sex, primary site and mutation status were found to be unrelated to Ki67. Many publications have reported that age, Breslow thickness, ulceration status, stage, primary site and LDH correlated to prognosis in AM patients (Teramoto et al. 2018; Wang et al. 2021; Wei et al. 2020; Wei et al. 2022a, b). However, the results have been conflicting for some variables. In our study, age, Breslow thickness, ulceration status, LDH and mutation status were not prognostic factors for MSS, whereas lymph node metastasis, primary site and Ki67 were independently associated with MSS. Wei et al. discovered the prognosis for sole melanoma was worse than for palm and nailbed subtypes (Wei et al. 2020), which is consistent with our findings. Ki67 expression in a continuous format was found to be an independent factor for MSS in our analyses, which was in alignment with the findings of Wang et al. (Wang et al. 2021). As a grouping variable, Ki67 was still independently correlated with MSS.

In this study, a nomogram prediction model incorporating Ki67 with other clinical parameters was constructed to predict 1-, 3-, 5-, and 8-year MSS rates in patients with AM. The impact of Ki67 expression on MSS was only surpassed by Breslow thickness, lymph node metastasis and primary site in this nomogram. The C-index values of the nomogram were both favorable in the training and validation cohorts. The AUC reached above 0.8 at the observed timepoints in the training cohort, and reached approximately 0.8 in the validation cohort. The nomogram achieved higher accuracy than that of AJCC staging system, as the NRI was above 0. The IDI showed that the predictive ability for 1-, 3-, 5- and 8-year survival was 0.5%, 10.0%, 12.8%, and 12.3%, respectively, compared with that of AJCC staging system.

Our established nomogram has certain advantages, especially in its practicality. First of all, the nomogram has integrated different prognostic and decisive variables that are easy to obtain and evaluate, which means it can help clinicians make an early assessment of the prognosis of patients with AM quickly and conveniently. In addition, the visual nomogram can enhance patients’ understanding, promote communication between doctors and patients, and improve patients’ cooperation. Furthermore, clinicians can identify patients with low overall survival earlier using this model, and then undertake more active and individualized treatments to improve the overall survival of AM patients.

There were some limitations in our study. First, some potential selection bias and information bias may exist as a result of the respective nature of the study. Secondly, the survival data may be affected by disease evolution and subsequent treatment; thus some accuracy of the nomogram might be sacrificed. Thirdly, this was a single-center study consisting of limited samples and we did not perform external validation for the nomogram. Therefore, the predictive model warrants further validation in a larger cohort, and a prospective study is required to elucidate the prognostic value of Ki67 for AM.

In this study, we described Ki67 expression in AM patients and analyzed its association with other clinicopathologic characteristics of AM patients. The results demonstrated that Ki67 as a stratification index can serve as an independent prognostic factor for AM patients. Furthermore, we have established the first nomogram incorporating Ki67 for AM patients based on a Chinese population, and the nomogram achieved better predictive power than the traditional AJCC staging system. The nomogram may thus help clinicians predict survival probability and guide individualized clinical therapy in AM patients in the future.